A landmark in non-invasive Esophageal Cancer diagnosis
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Proteomics International Laboratories Ltd. has announced the publication of clinical validation results for its PromarkerEso blood test, which can diagnose esophageal adenocarcinoma with high accuracy. The test demonstrated strong sensitivity and specificity in a study involving multiple patient cohorts, marking a significant advancement in non-invasive cancer diagnostics. Commercialization of PromarkerEso in Australia is expected soon, with plans to expand into other markets.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- $12 million capital raise completed with oversubscribed SPP
- PromarkerEndo latest results presented at world congress
- Chinese patent granted for OxiDx technology
- Share Purchase Plan Offer Booklet
- $4.5m placement to launch Promarker diagnostics
Later from Proteomics International Laboratories
- Supplementary Prospectus
- PromarkerD launched into the US at major diabetes conference
- First patent for endometriosis blood test - granted in Japan
- Funding boost for precision diagnostics Proteomics Facility
- AMA grants reimbursement code for Next-Gen PromarkerD test
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories